Ethyl 3-[[3-amino-4-(methylamino)benzoyl]-pyridin-2-ylamino]propanoate

We are Ethyl 3-[[3-amino-4-(methylamino)benzoyl]-pyridin-2-ylamino]propanoate CAS:212322-56-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Ethyl 3-[[3-amino-4-(methylamino)benzoyl]-pyridin-2-ylamino]propanoate
CAS.NO:212322-56-0
Synonyms:Ethyl 3-[[3-amino-4-(methylamino)benzoyl](pyridin-2-yl)amino]propionate
Ethyl 3-[3-Amino-4-(methylamino)-N-(2-pyridyl)benzamido]propionate
Molecular Formula:C18H22N4O3
Molecular Weight:342.39200
 
Physical and Chemical Properties:
Density:1.262
Boiling point:576.155ºC
Index of Refraction:1.64
 
Specification:
Appearance:White or pale yellow crystalline
Purity:≥98.0%
Single impurity:≤0.5%
Total impurities:≤1.0%
Residue on ignition:≤0.5%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Dabigatran etexilate
 
Note:The product under valid patents will not be offered to the countries covered by patents.

Ethyl 3-[[3-amino-4-(methylamino)benzoyl]-pyridin-2-ylamino]propanoate


Related News: Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.102849-49-0 Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.5-iodo-1-pentanol CAS:67133-88-4 Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.5720-05-8 Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,” said Mark Corbett, EVP, Inceptua Medicines Access.

Related Products
Product Name
2,4-Dichloro-7H-pyrrolo (2,3-d)pyrimidine View Details
2-ethylhexane-1-thiol View Details
3-UREIDOPROPYLTRIETHOXYSILANE View Details
2,3-dihydrobenzofuran manufacturer 2-Bromo-4-fluorophenol manufacturer 3,5-DI-O-(P-TOLUYL)-2-DEOXY-D-RIBOFURANOSYL CHLORIDE manufacturer 2-Anilinoethanol manufacturer (alphaR)-alpha-[[[2-(4-Aminophenyl)ethyl]amino]methyl]benzenemethanol hydrochloride manufacturer